DUBLIN, Sept. 26, 2017 /PRNewswire/ -- Today, Allergan plc (NYSE: AGN) is pleased to announce that ACZONE ® (dapsone) Gel, 7.5%, a prescription medicine used on the skin (topical) to treat acne in ...

Launch continues the expansion of Cosette’s generic portfolio and global partnership strategy BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (“Cosette”), in partnership with ...

The FINANCIAL — Allergan plc on February 25 announced that the Company has received approval from the U.S. Food and Drug Administration (FDA) to market ACZONE (dapsone) Gel, 7.5%, a new prescription ...

Allergan announced the discontinuation of Aczone (dapsone) 5% 30g tubes. Allergan announced the discontinuation of Aczone (dapsone) 5% 30g tubes. The last ship date was March 31, 2016 and the ...

The FDA has approved a new gel to treat acne. Aczone Gel 5%, made by QLT Inc., is approved to treat acne vulgaris. That's a common skin condition in which oil and dead skin cells clog the skin's pores ...

The Food and Drug Administration (FDA) has approved Aczone (dapsone; Almirall) Gel 7.5% for the topical treatment of acne vulgaris in patients aged ≥9 years. Previously, the treatment had been ...

Feb. 22, 2005 (New Orleans) -- A new topical gel containing 5% dapsone is showing promise in the treatment of acne vulgaris, according to results from two studies reported here at the 63rd annual ...

Now approved by the US FDA, Acrux’s generic Dapsone Gel, 7.5% treats acne in patients 9 years and up. Acrux (ASX:ACR) jumped by as high as 27% this morning after announcing the US Food and Drug ...

BRIDGEWATER, N.J.--(BUSINESS WIRE)--Cosette Pharmaceuticals, Inc. (“Cosette”), in partnership with SeegPharm SA (Lugano, Switzerland), is proud to announce the launch of Dapsone 5% Gel (NDC # ...

Acrux (ASX:ACR) jumped by as high as 27% this morning after announcing the US Food and Drug Administration's (FDA) approval of its generic version of Aczone Gel, 7.5% (Dapsone Gel, 7.5%). This ...